Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Non-Current Assets (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Other Non-Current Assets readings, the most recent being $1.9 million for Q1 2026.

  • Quarterly Other Non-Current Assets changed 0.0% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $1.9 million for FY2025, 1998.91% up from the prior year.
  • Other Non-Current Assets hit $1.9 million in Q1 2026 for Ovid Therapeutics, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.9 million in Q1 2024 and bottomed at $80114.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $1.9 million recorded in 2022.
  • The largest annual shift saw Other Non-Current Assets crashed 88.99% in 2023 before it soared 1998.91% in 2025.
  • Ovid Therapeutics' Other Non-Current Assets stood at $261191.0 in 2022, then dropped by 19.6% to $210000.0 in 2023, then plummeted by 56.19% to $92000.0 in 2024, then soared by 1998.91% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Other Non-Current Assets are $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q2 2025).